BI 765179

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 765179, covering 2026-04-14 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer [Phase 1]

See pricing